Yes, rivaroxaban 20 mg oral tablet is an FDA-approved anticoagulant specifically indicated for stroke prevention in non-valvular atrial fibrillation.
Rivaroxaban (Xarelto) 20 mg once daily is a direct factor Xa inhibitor approved by the FDA for reduction of risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation 1. This is one of its primary indications alongside warfarin and other direct oral anticoagulants (DOACs).
Mechanism and Administration
Rivaroxaban works by directly inhibiting factor Xa in the coagulation cascade 1. The standard dose of 20 mg must be taken once daily with the evening meal to ensure adequate absorption 1. This timing is critical—unlike some other anticoagulants, rivaroxaban's bioavailability depends on food intake.
Dosing Algorithm
The appropriate dose depends on renal function 2:
- CrCl >50 mL/min: 20 mg once daily (standard dose)
- CrCl 15-50 mL/min: 15 mg once daily (dose reduction required) 3, 4
- CrCl <15 mL/min or dialysis: Not recommended due to lack of clinical trial evidence 1
Common pitfall: The 20 mg dose is NOT appropriate for patients with moderate-to-severe renal impairment (CrCl 15-50 mL/min)—these patients require the 15 mg dose 2.
Evidence Base
The ROCKET AF trial established rivaroxaban's efficacy in 14,264 patients with non-valvular AF 1, 5. The trial demonstrated:
- Non-inferiority to warfarin for preventing stroke/systemic embolism (1.7% vs 2.2% per year, HR 0.79) 5
- Significantly less intracranial hemorrhage (0.5% vs 0.7%, P=0.02) and fatal bleeding (0.2% vs 0.5%, P=0.003) compared to warfarin 1, 5
- Similar major bleeding rates overall 5
- Higher gastrointestinal bleeding risk compared to warfarin 3
Clinical Recommendations
Rivaroxaban is recommended as a reasonable alternative to warfarin for patients with non-valvular AF and CHA₂DS₂-VASc score ≥2 1. The 2014 AHA/ACC/HRS guidelines give it a Class I, Level of Evidence B recommendation 1.
Key advantages over warfarin:
- No routine INR monitoring required
- Fixed dosing (no dose adjustments based on lab values)
- Fewer intracranial hemorrhages
- Once-daily administration
Important contraindications:
- Mechanical heart valves 1
- Moderate-to-severe mitral stenosis (valvular AF) 6
- End-stage renal disease or dialysis 1
Critical Safety Considerations
Must take with food: The evening meal requirement is not optional—absorption is significantly reduced without food 1.
No reversal agent was available at the time of the guidelines 7, though andexanet alfa has since been developed. This remains a consideration for high bleeding-risk procedures.
Drug interactions: Carbamazepine and other strong CYP3A4 inducers significantly reduce rivaroxaban levels and should be avoided 8.
Renal function monitoring: Unlike warfarin which doesn't require renal monitoring, rivaroxaban necessitates periodic creatinine clearance assessment since declining renal function increases stroke risk and may require dose adjustment 1.
The 20 mg dose is specifically the standard dose for stroke prevention in non-valvular AF with normal-to-mild renal impairment, making it a core therapeutic option in this indication 2, 6.